{"filing":{"accession_number":"0001034842-26-000043","cik":"0001034842","ticker":"RIGL","company_name":"RIGEL PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-06-17","report_date":null,"primary_document":"rigl-20260611.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1034842/000103484226000043/rigl-20260611.htm"},"events":[{"id":11539,"run_id":10135,"accession_number":"0001034842-26-000043","anchor_item_number":"2.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"The filing discloses completion of a License Agreement with Arvinas and Pfizer granting Rigel exclusive global rights to develop, manufacture, and commercialize VEPPANU™ (vepdegestrant). The transaction involved a $70.0 million upfront payment and required HSR clearance, constituting a material acquisition of asset rights that would affect investor assessment of the company's product pipeline and financial position.","company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","filing_date":"2026-06-17","submitted_at":null,"items":[{"id":8145,"accession_number":"0001034842-26-000043","item_number":"2.01","item_title":"Completion of Acquisition or Disposition of Assets.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses completion of a License Agreement with Arvinas and Pfizer granting Rigel exclusive global rights to develop, manufacture, and commercialize VEPPANU™ (vepdegestrant). The transaction involved a $70.0 million upfront payment and required HSR clearance, constituting a material acquisition of asset rights that would affect investor assessment of the company's product pipeline and financial position.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T20:08:50.010462+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8145,"accession_number":"0001034842-26-000043","item_number":"2.01","item_title":"Completion of Acquisition or Disposition of Assets.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses completion of a License Agreement with Arvinas and Pfizer granting Rigel exclusive global rights to develop, manufacture, and commercialize VEPPANU™ (vepdegestrant). The transaction involved a $70.0 million upfront payment and required HSR clearance, constituting a material acquisition of asset rights that would affect investor assessment of the company's product pipeline and financial position.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T20:08:50.010462+00:00","company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","filing_date":"2026-06-17"}]}